基于WHO/HAI标准化调查法对陕西省慢性病用药价格与供应情况的调查分析  

Investigation and Analysis of the Price and Supply of Medicines for Chronic Diseases in Shaanxi Province Using WHO/HAI Standardized Methodology

作　　者：姜明欢[1] 王乐[1] 王文娟[1] 王潇[1] 方宇[1] 杨世民[1] 

机构地区：[1]西安交通大学医学部药学院药事管理教研室,西安710061

出　　处：《中国药房》2013年第28期2598-2601,共4页China Pharmacy

基　　金：国家自然科学基金青年项目(No.71103141/G0308);中央高校基本科研业务费专项资金资助项目(No.2011jdhz62);陕西省社会科学基金资助项目(No.10E066);美国中华医学会(CMB)师资进修计划项目

摘　　要：目的:了解目前常见慢性病用药的价格和供应状况,为后续制定和完善相关政策提供循证支持。方法:采用世界卫生组织/国际健康行动机构(WHO/HAI)的标准化调查方法(手册第2版),于2012年对陕西省10个城市的120家公立医院和120家零售药店的27种慢性病用药的价格、可获得性和可负担性进行调查。结果:零售药店5类慢性病用药的可获得性均高于公立医院;神经系统用药可获得性最低,治疗心血管疾病和消化系统疾病的药物可获得性相对较高;用于神经系统的原研药零售价最高,而用于呼吸系统的原研药零售价最低;治疗心血管疾病的最低价格仿制药零售价最高,用于神经系统的最低价格仿制药零售价最低;使用原研药治疗慢性病,患者的可负担性均较差;除心血管疾病外,患者使用最低价格仿制药的可负担性均较好。结论:需保障慢性病用药的生产、供应,提高慢性病用药的可获得性;加强药品价格监管,降低部分慢性病用药的价格;增加慢性病用药报销比例,提高患者慢性病用药保障水平。ABST OBJECTIVE： To reveal the situation about the price and supply of medicines for chronic diseases in Shaanxi prov- ince, and to put forward some suggestions for the potential problems. METHODS： Using a standardized methodology （2nd edi- tion） developed by the World Health Organization （WHO） and Health Action International（HA1）, data on the price, availability and affordability of 27 kinds of medicines for chronic diseases was collected in 120 public hospitals and 120 retail pharmacies in 10 cities of Shaanxi province in 2012. RESULTS： The availability of five categories medicines for chronic diseases in retail pharma- cies is higher than in public hospitals. The availability of the medicines for nervous system disease is the lowest and the availability of the medicines for cardiovascular diseases and digestive system diseases is high. The retail price of originator brands for nervous system diseases is the highest, while the respiratory system disease is the lowest. However, the retail price of the lowest priced ge- netic equivalents for cardiovascular diseases is the highest, while the lowest in nervous system disease treatments. To use the origi- nator brands for treatment of chronic diseases, the affordability is poor; when the lowest priced generic equivalents are used, and the affordability is relatively high except for cardiovascular disease. CONCLUSIONS： It suggested ensuring the production and sup- ply of medicines for chronic diseases and improving the availability of them; strengthening the regulation of medicine price to re- duce the price of certain medicines for chronic diseases; increasing financial reimbursement to improve the security level of patients with chronic diseases.

关 键 词：慢性病用药 可获得性 价格 可负担性 陕西省 

分 类 号：R195[医药卫生—卫生统计学]